Passionate About Impact
Our leadership and management teams are focused on meeting patients’ needs in rare medical conditions and committed to delivering results for all Strongbridge stakeholders.
John H. Johnson
Chief Executive Officer
John was appointed to chief executive officer of Strongbridge in July 2020. He previously served as executive chairman from November 2019 to July 2020 and as chairman from March 2015 to November 2019. He is a recognized leader in the biopharmaceutical industry with more than 30 years of experience at leading global organizations, including Johnson & Johnson, Eli Lilly & Company, ImClone, and Pfizer, Inc. He currently serves as a member of the board of directors of Verastem, Inc. John previously served on the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.
John holds a BS from the East Stroudsburg University of Pennsylvania.
Richard S. Kollender
President and Chief Financial Officer
Prior to assuming the role of President and Chief Financial Officer, Richard served as Chief Operating Officer of Strongbridge since September 2019. Richard served as a member of the Company’s board of directors from March 2015 to September 2019. He brings more than 30 years of operational, business development and finance experience in the healthcare industry. Since 2003, he has served as a principal and partner of Quaker Partners, a healthcare investment firm. In addition, from August 2016 through September 2018, he served as chief business officer and chief financial officer of Rapid Micro Biosystems, a Quaker Partners’ portfolio company. Earlier in his career, Richard held positions in sales, marketing and worldwide business development at GlaxoSmithKline and served as investment manager at its corporate venture capital arm, S.R. One. Richard also practiced as a certified public accountant for six years at public accounting firms including KPMG. Richard currently serves as chairman of the board of directors for Restorative Therapies. He also serves on the board of directors for Rapid Micro Biosystems and as an adjunct faculty member at Lehigh University. He previously served on the board of directors of Insmed, NuPathe, Inc., and Celator Pharmaceuticals, Inc., among many other privately-held companies.
Richard holds an MBA and a certificate degree in the graduate program in health administration and policy, both from the University of Chicago and a BA in accounting from Franklin and Marshall College.
Fredric Cohen, MD
Chief Medical Officer
Fred joined Strongbridge in 2015 and has held roles of increasing responsibility, including senior vice president, global research and development, and vice president, clinical research and development. Fred is an endocrinologist by training with more than 20 years of drug and business development experience, most recently focused in development and commercialization of rare disease and specialty products. Prior to joining Strongbridge, Fred provided strategic and operational counsel to life science companies, actively supporting their development and licensing functions. Prior to that, he served as executive director, clinical pipeline, at Aptalis Pharma, where he was responsible for innovation strategy as well as building and advancing the company’s specialty pharma pipeline. He has also held research and development positions with Johnson & Johnson and Eli Lilly & Company.
Fred holds an MD from Pennsylvania State University College of Medicine and an AB in biology from Franklin and Marshall College.
Chief Compliance Officer
Brian brings more than 20 years of experience in developing, launching, implementing and managing effective global compliance programs. Prior to joining Strongbridge, he served as director at Huron Consulting Group, where he provided compliance design implementation support that considered both risk management and the business needs for medical device, pharmaceutical and biopharmaceutical companies. Prior, as the assistant compliance officer of the Americas for Shire Pharmaceuticals, Brian operationalized the company’s compliance program in the U.S. and Canada for the neuroscience, gastrointestinal and regenerative medicine business units. His in-depth industry knowledge includes extensive experience in rare disease markets within the areas of corporate ethics and compliance, general management, regulatory affairs, quality assurance, basic R&D, manufacturing, and sales/marketing.
Brian holds a BS in teacher preparation/biology from Drexel University.
Chief Human Resources Officer
Emily has more than 20 years of experience in human resources, organizational development, and talent acquisition in the biopharmaceutical industry. Her broad HR experience lends expertise to focus on talent development, culture building, and aligning internal communication and employee engagement strategy. Prior to joining Strongbridge in 2019, she held senior positions as vice president of global human resources at Globus Medical Inc. and head of HR for AstraZeneca’s diabetes franchise. Prior to joining AstraZeneca, she held progressively responsible roles in HR, sales and commercial learning at Shire Pharmaceuticals.
Emily holds a BS in healthcare management from Metropolitan State University of Denver and is currently pursuing her MS in human capital development from LaSalle University.
Chief Legal Officer
“We’re here to meet the challenges posed by rare diseases.”
Steve’s 20-year career has been focused on navigating the legal complexities faced by life sciences companies, including publicly traded, development, and commercial-stage firms. Corporate governance, transaction structuring and negotiation, complex litigation, compliance initiatives, intellectual property management, regulatory and clinical matters, and public company representation have all fallen under his purview. Steve has served as an attorney at Reed Smith LLP and spent 12 years at C.R. Bard, where he rose through the organization to become vice president, general counsel, and secretary. He has also served as assistant general counsel at Warner-Lambert Company.
Steve received his JD from Albany Law School of Union University and a BS from the School of Industrial and Labor Relations at Cornell University.
Chief Commercial Officer
Scott brings nearly 30 years of industry experience, most of which has been focused on commercializing products in a variety of rare disease categories. He most recently served as vice president, market and patient access at Marathon Pharmaceuticals, where he designed and developed the access strategy for the companies first commercial rare disease product. Previously, Scott served as vice president, market access and health services at PTC Therapeutics, leading the pre-launch market access strategy and tactical planning efforts for the company’s Duchenne Muscular Dystrophy treatment. In addition, he served as vice president, pricing, access and patient services at NPS Pharmaceuticals Inc. Scott has also served in a variety of positions with increasing responsibility at Clarus Therapeutics, Auxilium Pharmaceuticals, Biovail Corporation and Johnson & Johnson.
Scott served as a Field Artillery Officer in the U.S. Army and holds a BS in criminology from Missouri Western State University.
Senior Vice President, Sales
Dave has more than 25 years of commercial experience within the biopharmaceutical industry. Before joining Strongbridge, he served as vice president, rare disease and GI specialty sales at Shire Pharmaceuticals, where he directed multiple highly-specialized sales teams, focused on two rare diseases: hypoparathyroidism and short bowel syndrome. Prior, Dave served as vice president, neuroscience sales at Shire, where he successfully led the ADHD sales organization. In addition, he served in a variety of sales and marketing leadership positions at AstraZeneca.
Dave holds a BS in business administration from Central Michigan University.
Peter J. Valentinsson
Senior Vice President, Global Technical Operations
Pete has 25 years of technical operations experience in bringing new pharmaceutical products to the global marketplace, with specific experience in formulation development, process development, scale-up, technology transfer, and validation for both sterile and nonsterile products. He has held positions of increasing seniority at both large pharmaceutical and biotechnology companies, including serving most recently as vice president, global pharmaceutical sciences, at NPS Pharmaceuticals, Inc., which was acquired by Shire. Previously he served as senior director, pharmaceutical sciences quality, and also headed one of the product development groups at Schering-Plough Research Institute.
Pete holds an MS and a BS degree in chemical engineering from the New Jersey Institute of Technology.
Executive Leadership Team
John H. Johnson Chief Executive Officer
Richard S. Kollender President and Chief Financial Officer
Fredric Cohen, MD Chief Medical Officer
Brian Conner Chief Compliance Officer
Emily Doyle Chief Human Resources Officer
Stephen Long Chief Legal Officer
Scott Wilhoit Chief Commercial Officer
Dave Bonnell Senior Vice President, Sales
Peter J. Valentinsson Senior Vice President, Global Technical Operations